Anticancer drugs that induced cancer-associated cachectic sndromes

Expert Review of Anticancer Therapy

Volumn 2, Issue 1, 2002, Pages 121-129

  Tohgo, Akiko ^a   Kumazawa, Eiji ^a   Akahane, Kouichi ^a   Asakawa, Akihiro ^a   Inui, Akio ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anorexia; Anticancer drugs; Cachexia; Cancer; Chemotherapy; Mice; Taxanes

Indexed keywords

ALKALOID DERIVATIVE; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CAMPTOTHECIN DERIVATIVE; CHLORMETHINE; CILIARY NEUROTROPHIC FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; HORMONE INHIBITOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; LENTINAN; LEUPRORELIN; METHOTREXATE; MITOMYCIN C; TAMOXIFEN; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UFT; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; BODY WEIGHT; CACHEXIA; CANCER PATIENT; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; GROWTH INHIBITION; HUMAN; MEDICAL INFORMATION; MOUSE; NAUSEA AND VOMITING; NONHUMAN; QUALITY OF LIFE; RAT; REVIEW; SYMPTOMATOLOGY; TUMOR GROWTH; WASTING SYNDROME; ANIMAL; CHEMICALLY INDUCED DISORDER; NEOPLASM; SYNDROME;

ANIMALS; ANTINEOPLASTIC AGENTS; CACHEXIA; HUMANS; NEOPLASMS; SYNDROME;

EID: 0035983488     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.1.121     Document Type: Review

References (61)

1. Cancer anorexia-cachexia syndrome: Are neuropeptides the key?
2. Cytokine and sickness behavior: Implications from knockout animal models
3. Neuropeptide Y: A key molecule in anorexia and cachexia in wasting disorders?
4. Loss of skeletal muscle in cancer: Biochemical mechanisms
5. The symptoms of advanced cancer: Relationship to age, gender, and performance status in 1000 patients
6. Scoring a bull's-eye against cancer genome targets
7. Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor-α evaluated in gene knockout, tumor-bearing mice on C57 B1 background and cachexia
8. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways
9. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-α release via a mechanism involving IL-10
10. Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: Relationship with a proteolysis inducing factor
11. Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity
12. Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice
13. Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model
14. Role of endogenous tumor necrosis factor-α and interleukin 1 for experimental tumor growth and the development of cancer cachexia
15. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever
16. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130)
17. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor
18. Interleukin-6 involvement in mesothelioma pathobiology: Inhibition by interferon-α immunotherapy
19. Physiological effects of CNTF-induced wasting
20. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
21. Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice
22. In vivo effect of recombinant human leukemia inhibitory factor in primates
23. Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: Possible cellular mechanisms of cancer cachexia
24. Purification and characterization of a lipolytic factor (toxohormone-L) from cell-free fluid of ascites sarcoma 180
25. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host
26. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor
27. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients
28. Alterations in serum lipolytic activity of cancer patients with response to therapy
29. Induction of muscle protein degradation by a tumor factor
30. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer
31. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics
32. A Phase I study of LGD1069 in adults with advanced cancer
33. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
34. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy
35. New analogs of vitamin D3
36. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia
37. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
38. Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages
39. Enhancement of tumor radioresponse by docetaxel: Involvement of immune system
40. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications
41. Prolongation of survival period and improvement of cancer cachexia by long term administration of UFT
42. Anticachectic activity of 5′-Deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma
43. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine
44. Antitumor activity of various cytostatic in mice bearing murine advanced tumors
45. Animal models for the study of cancer-induced anorexia
46. Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice
47. Novel sulfonamides as potential, systemically active antitumor agents
48. Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine colon 38 tumor
49. Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon 26 and LX-1 models in mice
50. New chemotherapeutics in malignant mesothelioma: Effects on cell growth and IL-6 production
51. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: Validating the promise of molecularly targeted therapy
52. Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice
53. Anti-interferon-γ antibody treatment, growth of Lewis lung tumors in mice and tumor-associated cachexia
54. Abnormal gulutathione and sulfate levels after interleukin 6 treatment or tumor-induced cachexia
55. Activation of lipoprotein lipase and inhibition of B16-melanoma induced cachexia in mice by ponalrestat, an aldose reductase inhibitor
56. Cachexia induction by EL-4 lymphoma in mice and possible involvement of impaired lipoprotein lipase activity
57. Tumor growth, weight loss and cytokines in SCID mice
58. Identification of a human tumor-derived lipolysis-promoting factor
59. Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice
60. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
61. Humoral hypercalcemia of malignancy: Severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression